Page 5 - உருவகப்படுத்துதல்கள் ப்லஸ் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Drug modeling software company Simulations Plus Inc. beat analyst estimates for its second fiscal quarter, with net income increasing a whopping 49 percent. The Lancaster-based company, which makes a platform used by the pharmaceutical industry for drug research and development, reported an adjusted net income of $3.2 million (15 cents a share) for the quarter ended Feb. 28, compared to adjusted net income of $2.15 million (12 cents) for the same quarter a year ago. Revenue increased 27 percent year over year to $13.1 million. Analysts had expected earnings of 14 cents a share on revenue of $12.9 million, according to Zacks Consensus Estimate. “While we expect growth to normalize in the second half of our fiscal year, and are maintaining our full-year growth targets of 15 to 20 percent, this first-half performance underscores the strength and diversification of our business model,” Shawn O’Connor, chief executive at Simulations Plus, said during a conference call on Monday.

Shawn oconnorAmy stulickSimulations plus incSimulations plus increases net incomeSimulations plusZacks consensusSimualations plusஷான் ஒக்கொன்னோர்உருவகப்படுத்துதல்கள் ப்லஸ் இன்க்உருவகப்படுத்துதல்கள் ப்லஸ்ஜாக்கக்ஸ் ஒருமித்த கருத்து